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ABSTRACT
Multipotent mesenchymal stem cells (MSCs) have enormous potential in tissue engineering
and regenerative medicine. However, until now, their development for clinical use has been
severely limited as they are a mixed population of cells with varying capacities for lineage dif-
ferentiation and tissue formation. Here, we identify receptor tyrosine kinase-like orphan
receptor 2 (ROR2) as a cell surface marker expressed by those MSCs with an enhanced capac-
ity for cartilage formation. We generated clonal human MSC populations with varying capaci-
ties for chondrogenesis. ROR2 was identified through screening for upregulated genes in the
most chondrogenic clones. When isolated from uncloned populations, ROR21 ve MSCs were
significantly more chondrogenic than either ROR2–ve or unfractionated MSCs. In a sheep
cartilage-repair model, they produced significantly more defect filling with no loss of cartilage
quality compared with controls. ROR21 ve MSCs/perivascular cells were present in develop-
ing human cartilage, adult bone marrow, and adipose tissue. Their frequency in bone marrow
was significantly lower in patients with osteoarthritis (OA) than in controls. However, after
isolation of these cells and their initial expansion in vitro, there was greater ROR2 expression
in the population derived from OA patients compared with controls. Furthermore,
osteoarthritis-derived MSCs were better able to form cartilage than MSCs from control
patients in a tissue engineering assay. We conclude that MSCs expressing high levels of ROR2
provide a defined population capable of predictably enhanced cartilage production. STEM
CELLS 2017; 00:000–000
SIGNIFICANCE STATEMENT
Mesenchymal stem cells (MSCs) can be turned into cartilage-forming cells. However, these
stem cells vary from one donor to the other in their capacity to form cartilage and they lose
this capacity all together if they are grown for too long in the laboratory. A marker protein on
the surface of the stem cells might be used to predict which of them are best able to make
cartilage. The authors generated clones of MSCs and showed that some of the clones are very
good at making cartilage and some very poor at doing so. Through comparison of these clones,
a protein was identified, ROR2, that is present at higher levels on those MSCs that are very
good at making cartilage. This new marker may help to ensure a more effective cell therapy for
cartilage injuries.
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INTRODUCTION
A method of identifying and isolating mesenchy-
mal stem cells (MSCs) with an enhanced capac-
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been isolated from a number of anatomical locations in vivo
and are believed to be of perivascular origin, where cells includ-
ing pericytes are natural mesenchymal precursors [1, 2]. Once
cultured in vitro, MSCs are a heterogenous population deﬁned
by their capacity to adhere to tissue culture plastic and by their
ability to differentiate into cartilage, bone, and fat lineages.
Despite the absence of a deﬁnitive phenotypic marker, culture-
expanded MSCs have been deﬁned as expressing CD105, CD73,
CD44, and CD90 but lacking the expression of CD45, CD34,
CD14, CD11b, CD79a, CD19, and HLA-DR [3]. Although the des-
ignation of MSCs as a true stem cell population is questionable
[3–6], their capacity to undergo chondrogenic and osteogenic
differentiation [7, 8] is of clear therapeutic value. In particular,
MSCs hold great promise in the regeneration of cartilage
lesions. MSCs have been used to generate chondrocytes in vitro
[8, 9], for the tissue engineering of cartilage [10, 11] and in
numerous clinical studies. For example, one study has used
autologous MSC-generated chondrocytes to repair articular car-
tilage lesions in 40 patients with knee injuries [12]. We engi-
neered a 6-cm human airway using autologous MSCs that was
used successfully in the treatment of a patient with bronchial
stenosis [13, 14]. However, scale-up of these procedures for the
routine production of implantable cartilage of consistently high
quality remains a signiﬁcant challenge, in part because of the
lack of standardized methods for isolation of a functional cell
population optimized for chondrogenesis. A functional pheno-
typic marker for MSCs with enhanced chondrogenic potential
would reduce variability between patients in autologous proce-
dures and would also help to provide validation of the quality
of MSC lines used for allogeneic therapies and exploration of
the mechanisms of chondrogenesis. Here, we report the identi-
ﬁcation of inducible receptor tyrosine kinase-like orphan recep-
tor 2 (ROR2), the Wnt5a receptor, as a cell surface marker that
is predictive of signiﬁcantly enhanced chondrogenesis by MSCs,
allowing production of 35% more cartilage and 95% higher tis-
sue quality when used to repair cartilage lesions in sheep.
MATERIALS AND METHODS
Antibodies and Primers
Details of speciﬁcity and suppliers of all antibodies are shown
in Supporting Information Table S1. Details of all primers are
shown in Supporting Information Table S2.
Cell Types Used at Each Stage of Experimentation
Experimental work was undertaken in ﬁve stages using
ﬂuorescence-activated cell sorting (FACS)-sorted MSC clones,
unfractionated (whole population) MSCs, FACS-separated
ROR21 ve, and ROR2–ve populations or fresh bone marrow,
as described in Supporting Information Methods.
Cell Culture
Iliac crest bone marrow aspirates were obtained from patients
undergoing orthopedic surgery. All patients gave informed consent,
and the study was performed in full accordance with local ethics
guidelines (Southmead Research Ethics Committee Ref 78/01).
Bone marrow was added into tissue culture ﬂasks containing
expansion medium consisting of Dulbecco’s modiﬁed Eagle’s
medium supplemented with 1,000 mg/l glucose, 10% fetal bovine
serum from a selected batch (Thermo Scientiﬁc Hyclone,
Loughborough, UK, http://www.thermoﬁsher.com), 100 units/ml
penicillin, 100 lg/ml streptomycin (all from Sigma, Poole, UK,
http://www.sigmaaldrich.com), and 2 mM Glutamax-I (Invitrogen
Ltd, Paisley, UK, http://www.thermoﬁsher.com). Non-adherent cells
were removed during medium changes and adherent MSCs were
proliferated in the presence of 2 ng/ml ﬁbroblast growth factor-2
(FGF-2; PeproTech, London, UK, http://www.peprotech.com). MSCs
were passaged when 80% conﬂuent and preserved in liquid nitro-
gen until further use. After thawing, cells were proliferated further
in the presence of FGF-2 and the number of population doublings
(PDs) was calculated at each passage. Cellular senescence was
monitored regularly by staining for b-galactosidase activity (Senes-
cence Cells Histochemical Staining Kit; Sigma).
Sheep Model for Testing the In Vivo Chondrogenic
Capacity of MSCs
Full details of all operative procedures are described in Support-
ing Information Methods. Isolated inducible ROR2 (iROR2)1 ve
cells, ROR2–ve cells, or unfractionated whole population cells
from eight human donors were seeded onto polyglycolic acid
(PGA) scaffolds and used to engineer cartilage for 35 days as
described earlier. Bone marrow aspirates were obtained from
eight skeletally mature (over 4 years old) female English Mule
sheep (average weight 75.756 7.34 kg) and plastic-adherent
ovine MSCs were obtained by iliac crest biopsy and proliferated
using the same methods and reagents as described above for
human cells. The ovine MSCs were seeded dropwise at 1 3 106
cells per square centimeter onto Avitene Ultrafoam collagen
sponges (3 mm thickness; Bard, Crawley, UK, http://www.bar-
duk.com) and incubated overnight at 378C (Cell Bandage [15]).
A 6-mm diameter chondral defect was prepared in the left
medial femoral condyle of each of the sheep and lined with the
Cell Bandage before the human tissue engineered cartilage was
added to the defect and sutured in place. The implants
remained in vivo for 3 months before the sheep were killed. All
animal procedures were approved by the Royal Veterinary Col-
lege Ethics committee and carried out under a project licence
granted by the UK Home Ofﬁce (PPL 70/6964), in accordance
with the Animals (Scientiﬁc Procedures) Act of 1986.
Detailed methods are included in Supporting Information
online data.
RESULTS
Production of MSC Clonal Lines with Varying Capacity
for Chondrogenesis
Our strategy for identifying a cell surface marker, summarized in
Figure 1A, was to clone human MSCs by using a ﬂow cytometer
to deposit single bone marrow-derived MSCs into individual
wells of 96-well plates, without any antibody-based selection.
The cells were then expanded through multiple PDs, providing a
large enough number of cells of each clone for screening by car-
tilage tissue engineering and by subsequent gene array analysis
of individual undifferentiated clones. Each clone was cultured in
expansion medium containing 2 ng/ml FGF-2, which supports
the proliferation of single-cell-derived populations [16] and
maintains chondrogenic differentiation potential [17]. The single
cells began to divide after 2–3 days and those clones that contin-
ued to proliferate reached 90% conﬂuence in 13–22 days. They
were then passaged and re-seeded into 12-well plates and
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subsequently 25, 75, and 175 cm2 ﬂasks, as required, as they
continued to expand in number. The clones were prepared from
MSCs from six different patients, with varying cloning efﬁciency,
as shown in Supporting Information Table S3. Approximately
1 3 106 cells were needed to assess multilineage differentiation
and therefore each clone was required to undergo a minimum
of 20 PDs for further analysis. The amount of cellular senescence
in the clonal populations was estimated by staining for b-
galactosidase activity and those clones showing any evidence of
senescence were excluded from further investigation. Only
clones derived from one of the patient bone marrow samples,
PN5, were used for tissue engineering and gene array analysis.
We opted for use of clones from a single patient because of the
observation that this sample generated the majority of clones
and by excluding other samples we could reduce variability in
the screening procedure.
We analyzed 17 of the stable clones from PN5 and found
each one to have a unique capacity for cartilage formation, as
judged by type II collagen content of the engineered tissue mea-
sured using an epitope-speciﬁc enzyme linked immunosorbent
assay. The type II collagen content ranged from 1 to 383 mg per
tissue engineered construct (Supporting Information Table S4).
There was a signiﬁcant inverse correlation between the time
taken for the clones to undergo 20 PDs and the chondrogenic
potency as judged by the type II collagen content of tissue engi-
neered cartilage (Supporting Information Fig. S1). The same
clones were tested for their in vitro osteogenic and adipogenic
potential. As for chondrogenesis, there was a wide variation in
the differentiation capacity for these two pathways (Supporting
Information Fig. S2); however, the degree of osteogenesis or adi-
pogenesis did not correlate with the chondrogenic capacity (Sup-
porting Information Table S4).
We selected the four clones with the greatest capacity to
form cartilage (1–4) and the four clones with the poorest
capacity to form cartilage (14–17) based on their capacity for
type II collagen production (Fig. 1B) and further analyzed their
chondrogenic potential. Clones 1–4 were found to generate
cartilage with a signiﬁcantly higher dry weight (Fig. 1C), proteo-
glycan content (Fig. 1D), and collagen II/I ratio (Fig. 1E), than
clones 14–17. This analysis, therefore, validated our classiﬁcation
of clones 1–4 as highly chondrogenic and clones 14–17 as poorly
chondrogenic, enabling their use in screening studies.
Figure 1. Clonal analysis of human bone marrow mesenchymal stem cells (MSCs). (A): A scheme of the approach to isolating MSC
clones and analyzing each one for chondrogenic capacity and selected clones for mRNA expression by gene array. MSC isolation was by
plastic adhesion and proliferation through a number of population doublings with FGF-2, cloning was by unbiased ﬂow cytometry sort-
ing with no selecting antibody, chondrogenic capacity was by tissue engineering for 30 days on polyglycolic acid scaffolds and gene
expression was by Affymetrix gene array (size bars5 100 lm). (B): Chondrogenesis measured as the total type II collagen content by
enzyme linked immunosorbent assay, of tissue engineered cartilage (n5 1) made from unfractionated MSCs or MSC clones (1–17).
Insets show the typical appearance of tissue engineered cartilage. Cartilage engineered from the four most chondrogenic clones (1–4,
red bars) and the four least chondrogenic clones (14–17, blue bars) was further analyzed for dry weight of extracellular matrix formed
(C), content of proteoglycan measured as GAG (D), and the ratio of type II to type I collagen (E). Each scale bar is the mean6 SEM of
n5 4 clones. Comparison of differences between groups was by two-tailed Mann-Whitney U test. Abbreviations: ECM, extracellular
matrix; PD, population doubling; PGA, polyglycolic acid.
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Identification of a Marker of Selected Clonal Lines by
Gene Array Analysis
We isolated the mRNA of undifferentiated cells from the highly
and poorly chondrogenic clones that had been expanded with
FGF-2 and serum to prime them for chondrogenic differentia-
tion, but not yet induced to differentiate with transforming
growth factor (TGF)-b3. We went on to investigate differential
gene expression between the two groups, to identify genes
predictive of enhanced chondrogenic potential upon subse-
quent differentiation. Ontological analysis of the function of
those genes differentially upregulated by the highly chondro-
genic clones indicated that the majority of those with a known
function were cell signaling genes (Fig. 2A; Supporting Informa-
tion Table S5). This is important as cell signaling pathways play
a critical role in determining the differentiation fate of MSCs.
Heat map analysis of the genes that were upregulated on
highly chondrogenic clones 1–4 compared with poorly chondro-
genic clones 14–17 conﬁrmed that there was clustering of
upregulated genes between these two groups (Fig. 2B). The 82
genes shown in this heat map are listed in Supporting Informa-
tion Table S6 in order of statistical signiﬁcance of the differen-
tial expression between clone groups. As the purpose of this
study was to identify cell surface markers predictive of chon-
drogenesis, we selected a subset of 24 of the differentially
expressed genes that contained at least one membrane-
spanning domain (Supporting Information Table S7). Only one
of the genes, ROR2, showed a clear differential protein expres-
sion upon preliminary analysis by ﬂow cytometry (Fig. 2C). Dif-
ferential upregulation of ROR2 mRNA and protein was
conﬁrmed as signiﬁcant (four highly chondrogenic clones com-
pared with four poorly chondrogenic clones) by real time quan-
titative polymerase chain reaction (Fig. 2D) and ﬂow cytometry
(Fig. 2E), respectively.
Induction of ROR2 Expression by Chondrogenic MSCs
Initial observations indicated higher ROR2 gene expression in
when MSCs were cultured at a high cell density. As illustrated
in Figure 3A, undifferentiated MSC clones were grown to low
Figure 2. Identiﬁcation of cell surface markers upregulated on highly chondrogenic mesenchymal stem cell clones. (A): Ontology of
genes signiﬁcantly upregulated on highly chondrogenic clones. The chart shows the function of those genes which are at least 1.3-fold
upregulated on the four most highly chondrogenic clones (clones 1–4) in comparison with the four least chondrogenic clones (clones
14–17). Only genes showing a signiﬁcant change in p< .05 are included (two-way analysis of variance). (B): Heatmap and hierarchical
clustering of the 82 genes that were signiﬁcantly upregulated on the highly chondrogenic clones. Each column is one clone and each
row is one gene. (C): Flow cytometry analysis of the percentage of cells expressing each of six proteins identiﬁed from the gene array
analysis and known to contain membrane-spanning domains. Red bars are results for one highly chondrogenic clone (clone 1) and blue
bars are results for one poorly chondrogenic clone (clone 15). The proteins analyzed were stathmin-like 2 (STMN2), asporin (ASPN),
plexin domain containing 2 (PLXDC2), ﬁbroblast growth factor receptor 2 (FGFR2), doublecortin-like kinase 1 (DCLK1), and receptor tyro-
sine kinase-like orphan receptor 2 (ROR2). (D): Real-time quantitative polymerase chain reaction analysis of ROR2 gene expression and
(E) ﬂow cytometry analysis of ROR2 protein expression by the four highly chondrogenic clones 1–4 (red bars) and four poorly chondro-
genic clones 14–17 (blue bars). Each bar is the mean6 SEM of n5 4 clones. Comparison of differences between groups was by two-
tailed Mann-Whitney U test. Abbreviation: ROR2, receptor tyrosine kinase-like orphan receptor 2.
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density, where cell-to-cell contact was minimal (mean6 SEM
of 7,137 6 584 cells per square centimeter), to conﬂuence
(38,083 6 6,515 cells per square centimeter) or to high den-
sity, where 100% conﬂuent cells were maintained in culture
for an additional 6 days (46,417 6 7,494 cells per square cen-
timeter). ROR2 protein expression was then determined by
ﬂow cytometry for cells at each density (Fig. 3B). For highly
chondrogenic clones 1–4, we observed a clear increase in
ROR2 expression with increasing cell density, whereas there
was minimal expression of ROR2 on the poorly chondrogenic
clones even in high density culture (Fig. 3C). These data dem-
onstrate that the highly chondrogenic clones can be induced
to express ROR2. For the remainder of this article, we have,
therefore, adopted the terminology of iROR21 ve cells to
describe cultured cells showing an increased ROR2 expression,
induced through increasing cell density in culture. MSCs which
do not show any increase in ROR2 during culture expansion
are described as ROR2 negative (ROR2–ve) cells. ROR2 expres-
sion on uncultured MSCs is referred to as percentage ROR2
expression relative to another cell surface marker.
We went on to investigate ROR2 expression by unfractio-
nated/uncloned MSCs from four different patients. There was a
clear increase in ROR2 expression with increasing cell density
for all four patients, although there was also marked variation
in the extent of expression between the different patients (Fig.
3D). When these cells were passaged and replated at low den-
sity, there was a marked fall in ROR2 expression over the ﬁrst
3 days of the new passage (Fig. 3E). Therefore, for all subse-
quent studies, ROR2 expression was measured only after the
cells had been grown to high density, allowing comparison to
be made between different subsets of cells.
Isolation and Characterisation of iROR21Ve and
ROR2–ve MSCs
To study further, the iROR21 ve MSCs identiﬁed in the
unfractionated population, it was essential to isolate them, as
well as ROR2–ve MSCs, as separate populations. We were
able to isolate iROR21 ve and ROR2–ve MSCs from conﬂuent
cultures of the unfractionated cells by labeling with an anti-
ROR2 antibody and using sterile cell sorting to collect the dif-
ferent populations. (Fig. 4A). The experiment was repeated
using MSCs from n5 8 donors with a ﬁnal purity (mean6
SEM) of 97.3%6 0.7% for ROR2–ve and 90.2%6 0.4% for
iROR21 ve MSCs.
Figure 3. Upregulation of receptor tyrosine kinase-like orphan receptor 2 (ROR2) protein expression by increased cell density. Mesen-
chymal stem cells (MSCs) were seeded into tissue culture ﬂasks and harvested for analysis of ROR2 expression by ﬂow cytometry after
growing to low density (3–6 days), conﬂuence (7–14 days), or high density (14–18 days). (A): The typical appearance of MSCs at each
density range. Scale bar5 100 lm. (B): Detection of ROR2 by ﬂow cytometry in a representative sample of cells at each density range.
Events in red are cells labeled with isotype control antibody and events in blue are cells labeled with anti-ROR2 antibody and detected
using PE ﬂuorescence. (C): Analysis of ROR2 expression at different cell densities on highly chondrogenic clones 1–4 (red bars) and
poorly chondrogenic clones 14–17 (blue bars). Each bar is the mean6 SEM of n5 4 clones. Comparison of differences between groups
was by two-tailed Mann-Whitney U test. (D): Analysis of ROR2 expression at different cell densities on unfractionated MSCs from four
different donors without passage of the cells during the experiment. Each line represents one donor. (E): Analysis of ROR2 expression at
different cell densities on unfractionated MSCs from four different donors before and after passage. Each line represents one donor.
Abbreviations: Con, conﬂuent; ROR2, receptor tyrosine kinase-like orphan receptor 2; PE, phycoerythrin.
Dickinson et al. 5
www.StemCells.com VC AlphaMed Press 2017
While we hypothesize that the iROR21 ve MSCs will be
more highly chondrogenic than iROR2–ve MSCs, it is important
to determine whether both of these populations have retained
the characteristics of MSCs, namely expression of established
cell surface markers, multidifferentiation capacity and pro-
longed proliferative life-span. We, therefore, started our ana-
lyzes by testing each of these stem cell attributions before
going on to determine the chondrogenic potential of these
MSCs. A range of cell surface markers have been used to deﬁne
the unfractionated MSC population [3], and we, therefore, con-
sidered it important to know if iROR2 expression was associated
with either an increase or a decrease in expression of these
known markers. We, therefore, determined levels of nine differ-
ent markers by ﬂow cytometry, comparing iROR21 ve MSCs
with ROR2–ve and unfractionated MSCs. There were no signiﬁ-
cant differences in the expression of CD105, CD90, CD73,
VCAM1, STRO-1, CD146, CD271, CD34, and CD45 between the
different MSC populations (Fig. 4B), demonstrating that ROR2 is
an independent marker, not directly associated with any of the
known markers currently used to deﬁne this type of stem cell.
The iROR21 ve, ROR2–ve, and unfractionated populations of
MSCs were all multipotential progenitor cells as judged by their
capacity to differentiate to more than one lineage and there
was no apparent difference between the populations in their
capacity to undergo osteogenesis (Fig. 4C) or adipogenesis (Fig.
4D). These data indicate that the iROR21 ve and ROR2–ve cells
have each retained their MSC properties and any differences
observed in chondrogenic capacity must, therefore, be a result
of differences in stem cell potential rather than stage of differ-
entiation of the cell subsets.
If ROR2 selection is to be of practical use, it is important
to determine whether the isolated iROR21 ve cells retain a
higher expression of this marker after multiple PDs. Figure 4E
shows that over six passages, the isolated ROR2–ve popula-
tion remained negative throughout, never recovering the
capacity to upregulate ROR2. The iROR21 ve and unfractio-
nated populations both gradually lost expression of iROR2
with increasing passage number; however, the iROR21 ve
Figure 4. Characterization of inducible receptor tyrosine kinase-like orphan receptor 2 (iROR2)1 ve and ROR2–ve mesenchymal stem
cell (MSC) populations. (A): MSCs were grown to high density and the iROR21 ve and ROR2–ve populations were isolated using sterile
ﬂow cytometry. (B): Sorted or unfractionated MSCs were analyzed by ﬂow cytometry for the expression of marker proteins. Population
frequencies for each marker are shown below the plots (mean6 SEM; n5 6). There was no statistically signiﬁcant difference in any of
the marker proteins (Kruskal-Wallis). (C): Osteogenic differentiation of the sorted and unfractionated (Un) populations from n5 6 donors
shown by alizarin red staining (size bars5 100 lm) and by real-time quantitative polymerase chain reaction (qPCR) for integrin-binding
sialoprotein (bone sialoprotein) and alkaline phosphatase. There were no signiﬁcant differences in gene expression (Kruskal-Wallis). (D):
Adipogenic differentiation of the sorted and unfractionated (Un) populations from n5 6 donors shown by oil red O staining (scale
bars5 100 lm) and by real-time qPCR for lipoprotein lipase and fatty acid binding protein 4. There were no signiﬁcant differences in
gene expression (Kruskal-Wallis). (E): Maintenance of the iROR21 ve and –ve phenotypes was tested for six passages after sorting. Each
point is the mean6 SEM; n5 6 for each population). *, p5 0.2000; **, p5 0.0294; ***, p5 0.0286 versus the unfractionated whole
population, by two-tailed Mann-Whitney U test. (F): Suppression of lymphocyte proliferation by MSCs. The percentage inhibition of lym-
phocyte proliferation was measured after coculture of the mononuclear cells with sorted or unfractionated (Un) MSCs from n5 5
donors. Statistical analysis was by paired t test. Abbreviations: FABP4, fatty acid binding protein 4; IBSP, integrin-binding sialoprotein;
LPL, lipoprotein lipase; PE, phycoerythrin; ROR2, receptor tyrosine kinase-like orphan receptor 2.
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fraction retained a signiﬁcantly raised expression of ROR2
compared with unfractionated cells at all passages. The fall in
ROR2 expression with increasing passage is coincident with a
reduced capacity for chondrogenesis. This is illustrated by the
macroscopic appearance of tissue engineered cartilage made
from early and late passage MSCs (Supporting Information
Fig. S3A, S3B) and the decreased content of cartilage speciﬁc
molecules at late compared with early passages (Supporting
Information Fig. S3C, S3D). Nevertheless, the consistently
raised level of iROR2 compared with controls throughout this
extended culture period indicates that the phenotype is rela-
tively stable and that the beneﬁt of selection may be main-
tained as the cells are expanded.
MSCs have been previously shown to be immunoregulatory,
suppressing third party T-cell proliferation [18–20]. We, there-
fore, compared iROR21 ve MSCs with ROR2–ve and unfractio-
nated MSCs for their capacity to inhibit T-cell proliferation in
vitro. This important property of MSCs was no different in
iROR21 ve and unfractionated MSCs; however, for each of the
ﬁve patients studied, ROR2–ve MSCs had a lower capacity to
inhibit T-cell proliferation compared with iROR21 ve or unfrac-
tionated populations and this difference was signiﬁcant (Fig. 4F).
Functional Advantage of iROR21ve in Cartilage Tissue
Engineering In Vitro
MSCs were isolated from eight patients and then either fraction-
ated into the iROR21 ve and ROR2–ve populations or cultured
without fractionation as a control. The three subpopulations
from each donor were each seeded onto polyglycolic acid scaf-
folds and cartilage tissue engineering was induced using a com-
bination of TGFb3, ascorbic acid, and insulin. Typical examples of
the macroscopic appearance of cartilage after 35 days in vitro
are shown in Figure 5A, illustrating a tendency for larger
amounts of tissue to be formed by the iROR21 ve cells. This
observation is conﬁrmed by the signiﬁcantly higher dry weights
of cartilage constructs engineered using iROR21 ve MSCs com-
pared with either ROR2–ve MSCs or unfractionated controls and
by the detailed biochemical analysis of the tissue engineered
cartilage from each MSC sub-population from all 8 donors (Fig.
5B). Whether comparing iROR21 ve cells with unfractionated
MSCs or with the ROR2–ve fraction, there was a signiﬁcantly
higher content of both type II collagen and proteoglycan. Low
and high power immunolocalization for collagen II and histologi-
cal staining for proteoglycans or extracellular matrix (ECM) also
shows a more extensive cartilage formation when using
iROR21 ve cells to engineer cartilage (Fig. 5C).
Therapeutic Advantage of iROR21ve over Unfractionated
MSCs in a Sheep Cartilage Repair Model
We established a functionally loaded in vivo model for the
implantation of human tissue engineered cartilage into full
thickness articular cartilage lesions in the ovine medial femoral
condyle without the use of immunosuppressive drugs. Immune
rejection was avoided in this model because we implanted a
“Cell Bandage” formed from sheep undifferentiated MSCs
seeded onto a collagen sponge at the interface between host
and implant (Supporting Information Fig. S4). We designed the
Cell Bandage as a mechanism for driving integration of cartilage
[15, 21]; however, the undifferentiated MSCs are also immuno-
regulatory [22] and so will create a zone of tolerance at the
interface site. Additional protection from immune rejection
may have resulted from growing the engineered cartilage in
vitro for 35 days, allowing a dense ECM to become established
before implantation, creating an immune privileged site
through physical inhibition of the migration of elements of the
immune system. In preliminary experiments using unfractio-
nated cells, we observed through histological analysis, 3
months after implantation of engineered cartilage, that there
were no signs of inﬂammation; however, there was generally a
failure of the implants to integrate laterally with the surround-
ing host cartilage (Fig. 5D, upper panels). Following the prelimi-
nary studies, cartilage engineered using iROR21 ve, ROR2–ve,
or unfractionated MSCs from eight human donors was
implanted into defect sites in this sheep model. The extent and
quality of cartilage repair after 3 months were measured as
percentage defect ﬁlling measured macroscopically by morpho-
metric analysis and biochemical quality measured as the per-
centage GAG and percentage type II collagen in the repair
tissue. Defect ﬁlling over 90% of the defect sites was observed
in those animals treated using cartilage from iROR21 ve MSCs,
whereas in those treated using cartilage from unfractionated or
ROR2–ve MSCs, there was signiﬁcantly less defect ﬁlling (Fig.
5E). Regenerated tissue was dissected from the implant site
and analyzed for content of type II collagen and proteoglycans,
in comparison with samples of the preimplantation tissue-
engineered cartilage, allowing an assessment of maturation of
the implants over 3 months. There was a large and signiﬁcant
increase in the type II collagen content of implants, irrespective
of which MSC fraction as used whereas the proteoglycans con-
tent decreased signiﬁcantly during the same period in vivo.
(Fig. 5D, lower panels). Overall, these data show improved
quality of cartilage measured biochemically in all three treat-
ment groups with no apparent advantage of iROR21 ve MSCs.
However, there was clearly a greater abundance of repair tis-
sue, with no loss of tissue quality, when using iROR21 ve
MSCs compared with control groups, measured as defect ﬁlling,
indicating the potential therapeutic advantage of this cell
population.
Native Origin of ROR21 Cells
We considered it important to determine whether the
iROR21 ve cells observed in expanded, adherent MSCs are a
consequence of tissue culture conditions or whether they exist
in situ and in freshly isolated cells before adhesion to plastic
for culture. Since ROR2 is thought to be important in limb bud
development [23], sections of human fetal developing ulna
limb bud (developing arm bones) were immunostained for
ROR2 and for MSC-related markers, CD105 and CD90. Since
the natural precursor of MSCs in vivo is a perivascular cell,
including the pericyte, the limb buds were also stained for the
pericyte marker CD146. ROR21 ve cells were found in the
bone marrow stroma as well as surrounding the blood vessels
of limb bud from 11–12 week old human fetuses (Fig. 6A).
These cells were colocated with cells positive for CD105 and
CD90 as well as CD146, whereas there were no osteocalcin
positive (bone-forming) cells in these regions (Fig. 6A). These
data support the theory that endogenous MSCs and their natu-
ral precursor, the pericyte, express ROR2 in development. Fur-
thermore, a small number of ROR21 ve cells were also
observed surrounding the blood vessels of adult human bone
marrow tissue sections, again colocated with CD1461 ve cells
(Supporting Information Fig. S5), suggesting that ROR21 ve
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mesenchymal lineage cells are naturally occurring rather than
resulting from tissue culture.
To further investigate the naturally occurring ROR21 ve
mesenchymal cells in human adult tissues, we used ﬂow cytom-
etry to determine their occurrence in uncultured mononuclear
cell populations that had been freshly isolated from adult bone
marrow and adipose. Within the CD1051 ve, CD34–ve MSC
population (Fig. 6B), we observed a small percentage of
ROR21 ve cells that was not signiﬁcantly different between
bone marrow (mean6 SEM of 3.06 0.6%) and adipose (9.3%6
3.4%). Within the CD1461 ve, CD34–ve pericyte population
(Supporting Information Fig. S6C), we also observed a small per-
centage of ROR21 ve cells in bone marrow (mean6 SEM of
3.3%6 0.4%), but a signiﬁcantly higher percentage in adipose
(17.7%6 4.6%). These data conﬁrm that ROR21 ve MSCs/peri-
cytes are naturally occurring. Furthermore, in adults, they are
not restricted to bone marrow but can be found in at least one
other site in the body.
Having established that ROR2 is expressed on low num-
bers of freshly isolated MSCs, we then determined how many
passages were required to reach maximal ROR2 upregulation
in culture. Bone marrow derived MSCs were seeded onto tis-
sue culture plastic and analyzed for ROR2, after growing to
high density, at the end of each passage. After initial adher-
ence to and growth on tissue culture plastic there was a
marked upregulation of iROR2, reaching a maximum at the
end of passage 1 (Supporting Information Fig. S7). This coin-
cides with a high capacity for cartilage formation at early pas-
sage (Supporting Information Fig. S3). Subsequently, there
was a decrease in iROR2 expression at each passage that cor-
relates with the gradual fall in chondrogenic capacity over
multiple passages.
ROR2 Changes with Age and Osteoarthritis
Osteoarthritis (OA) is a disease of ageing in which there is
typically a loss of articular cartilage as the disease progresses.
Figure 5. Enhanced chondrogenic capacity of inducible receptor tyrosine kinase-like orphan receptor 21 ve mesenchymal stem cell
(MSC). Sorted or unfractionated human MSCs were used for cartilage tissue engineering and analyzed after 35 days in vitro (A–C) or
after 3 months in vivo in a sheep model (D, E). In (A), the typical macroscopic appearance is shown for duplicate cartilage constructs
engineered from unfractionated or sorted MSCs in vitro. (B): The biochemical content of tissue engineered cartilage (mean6 SEM;
n5 8). Statistical analysis by Wilcoxon matched pairs test. (C): Low-magniﬁcation (column 1, scale bar5 1,000 lm) and high-
magniﬁcation (columns 2–4, size bar5 100 lm) histological images stained for type II collagen, with safranin-O for proteoglycan (GAG)
or with H&E. (D): Cartilage engineered from sorted or unfractionated MSCs from eight human donors were implanted into defects
within the femoral condyles of sheep stiﬂe joints without immunosuppression. Upper panels show safranin-O staining (scale bar5 100
lm). The percentage proteoglycan content (measured as GAG) and percentage Type II collagen content was measured immediately
before implantation (purple bars) or 3 months after implantation (red bars). Statistical analysis by Wilcoxon matched pairs test. (E):
Defect ﬁlling in the sheep cartilage repair model after 3 months. The in situ appearance of representative samples is shown, with the
integration site between the natural sheep cartilage and the implanted human cartilage indicated. The defect ﬁlling was measured for
each sample and expressed as a percentage of total area (n5 8 for each experimental group). Statistical analysis was by Wilcoxon
matched pairs test. Abbreviations: HC, human cartilage; iROR2, inducible ROR2; ROR2, receptor tyrosine kinase-like orphan receptor 2;
SC, sheep cartilage; Un, unfractionated.
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We were, therefore, interested in whether there is a deﬁ-
ciency of ROR2 expression by MSCs in OA and whether this is
related to increasing age. We ﬁrst analyzed the ROR2 expres-
sion on freshly isolated CD1461 ve, CD34–ve pericytes (Fig.
7A–7C) and CD1051 ve, CD34–ve MSCs (Fig. 7D, 7E). MSCs/
pericytes from OA patient bone marrow expressed signiﬁ-
cantly less ROR2 than MSCs/pericytes from non-OA bone mar-
row (Fig. 7B, 7C) and this was not a feature of aging since
there was no apparent correlation between age of the donor
and ROR2 expression (Figs. 7E, 7F). In parallel experiments,
we isolated plastic-adherent MSCs from OA and non-OA
patients and stimulated maximal ROR2 expression by growing
them to conﬂuence before determining ROR2 by ﬂow cytome-
try. There was a tendency for much higher expression of
ROR2 in conﬂuent OA MSCs compared with non-OA (Fig. 7G),
although this did not reach statistical signiﬁcance. This might
be explained in part by age of the patient since the age distri-
bution for the OA donors was higher than the control group
and there was a weak correlation between donor age and
maximal ROR2 expression, although these differences were
not signiﬁcant (Figs. 7H, 7I). If OA MSCs do in fact express
higher levels of ROR2 than non-OA MSCs then they should
also be better at generating cartilage. To test this hypothesis,
we used MSCs from each group in cartilage tissue engineering
and found that the OA MSCs produced cartilage with higher
weight and greater proteoglycans and type II collagen content
than non-OA MSCs (Fig. 7J–7L).
DISCUSSION
Predictive functional MSC markers are critical for ensuring
improved therapeutic outcomes and meeting regulatory
demands when implanting MSC-derived tissue engineering
products into patients. It is widely recognized that the avail-
able MSC markers are not predictive of functional capacity
and that new markers relating to subsets of this heteroge-
neous stem cell population will be required to move the ﬁeld
forward [24, 25]. We have successfully used a genomic proﬁl-
ing strategy to identify an MSC cell surface marker that is pre-
dictive of enhanced chondrogenesis. Previous studies have
focused on changes in gene expression after the initiation of
speciﬁc differentiation pathways, or comparing gene expres-
sion patterns for MSCs isolated from different tissues [26]. In
contrast, we have studied the gene expression pattern of
undifferentiated MSC clones deﬁned according to their
Figure 6. The in vivo and ex vivo origin of receptor tyrosine kinase-like orphan receptor 2 (ROR2)1 ve cells in human tissues. (A):
Immunolocalisation of ROR2, in comparison with the mesenchymal stem cell marker proteins CD105 and CD90, the pericyte marker
CD146 and the osteogenic marker osteocalcin, in the developing ulna limb bud from a human fetus of 11–12 weeks gestation. Regions
of bone marrow stroma and blood vessels are shown. In all cases, DAB chromagen (brown) was used for visualization of positive signal
and hematoxylin (purple) was used as a nuclear counter-stain (scale bar5 20 lm). ROR2 expression was also analyzed in samples of
fresh, uncultured adult human bone marrow and adipose tissue [panels (B) and (C)] to determine the proportion of cells expressing
ROR2 on initial isolation. Mononuclear cells were isolated from fresh bone marrow (n5 5) or adipose tissue (n5 4) and immediately
analyzed by ﬂow cytometry following incubation with antibodies against CD105, CD146, CD34, and ROR2. Representative ﬂow cytometry
plots are shown and the graphs show the percentage of viable CD1051/CD34– [panel (B)] and CD1461/CD34– [panel (C)] cells that
express ROR2. Comparison of differences between groups was by two-tailed Mann-Whitney U test. Abbreviations: APC, allophycocyanin;
FITC, ﬂuorescein isothiocyanate; PE, phycoerythrin; ROR2, receptor tyrosine kinase-like orphan receptor 2.
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subsequent capacity to undergo chondrogenesis, so testing
the predictive value of any genes that are differentially upre-
gulated in those MSCs that are destined to be highly chondro-
genic. This general approach could be applied to other cell
differentiation pathways. While previous studies have pro-
vided some evidence for predictive chondrogenic markers in
high-density pellet cultures assays [27], we have been able to
use iROR2 selection to generate an improved three-
dimensional tissue engineered cartilage that had greater efﬁ-
cacy in a sheep cartilage-repair model than unfractionated
MSCs and so could potentially be of therapeutic beneﬁt in
human patients.
The success of our cloning approach depended on our
well deﬁned cartilage tissue engineering protocol [11] and
type II collagen immunoassay. We developed the assay origi-
nally as a method of studying osteoarthritic cartilage [28] and
then further reﬁned it for the study of cartilage regeneration
quality in patient biopsies [29]. Our quantitative analyses
showed a wide range of cartilage tissue engineering outcomes
from one clone to another with no apparent correlation to
Figure 7. Variation in receptor tyrosine kinase-like orphan receptor 2 (ROR2) with age and in patients with osteoarthritis (OA). In pan-
els (A–F), ROR2 expression was analyzed in samples of fresh, uncultured adult human bone marrow to determine the proportion of cells
expressing ROR2. Mononuclear cells were isolated using Ficoll separation and immediately analyzed by ﬂow cytometry following incuba-
tion with antibodies against CD105, CD34, and ROR2 or CD146, CD34, and ROR2. Representative ﬂow cytometry plots are shown for
both CD1461/CD34– pericytes (A) and CD1051/CD34– mesenchymal stem cells (MSCs) (D). The percentage of cells in fresh bone mar-
row which express ROR2 isolated from donors with and without OA (non-OA n5 5, OA n5 8) are shown for both CD1461/CD34– peri-
cytes (B) and CD1051/CD34– MSCs (E). Statistical analysis by Mann-Whitney U test. The correlation of ROR2 expression with age of
donor is shown for both CD1461/CD34– pericytes (C) and CD1051/CD34– MSCs (F). Spearman rank correlation coefﬁcients are shown.
In panels (G–I) ROR2 expression was analyzed by ﬂow cytometry after isolation of MSCs and their subsequent expansion in vitro. Results
are shown as the percentage of ROR21 ve cells at the time of ﬁrst passage [p0, panel (G), statistical analysis by Mann Whitney U test]
and as correlation with donor age [panel (I), Spearman rank correlation coefﬁcient is shown]. The age-range of patients in the non-OA
and OA groups is shown in panel h (statistical analysis by two-tailed Mann-Whitney U test). In panels (J–L), results are shown for carti-
lage tissue engineering using MSCs isolated from either non-OA (n5 4) or OA (n5 4) patients. Statistical analysis by Mann-Whitney U
test. Abbreviations: ECM, extracellular matrix; FITC, ﬂuorescein isothiocyanate; MSC, mesenchymal stem cell; OA, osteoarthritis; PE, phy-
coerythrin; ROR2, receptor tyrosine kinase-like orphan receptor 2.
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osteogenic or adipogenic potential (Supporting Information
Table S4). Two previous studies have described the cloning of
MSCs from bone marrow by limiting dilution [16, 30], and
these are in agreement with our data (Supporting Information
Fig. S1), indicating that more rapidly proliferating MSC clones
are better able to differentiate. A total of 82 genes were
found to be signiﬁcantly upregulated in the highly chondro-
genic MSCs compared with the poorly chondrogenic clones.
Our gene and subsequent ﬂow cytometry screening identiﬁed
ROR2 as being upregulated on the surface of highly chondro-
genic clones.
We were encouraged to investigate this molecule because
of its well-described importance in limb development [23,
31–33]. ROR1 and ROR2 were ﬁrst identiﬁed by Masiakowski
and Carroll, who recognized the importance of tyrosine kinase
in growth factor receptor function and, therefore, screened
for novel genes encoding proteins with a tyrosine-kinase like
cytoplasmic domain [34]. A series of important studies then
identiﬁed ROR2 as playing a key role in cartilage and growth
plate development in the limb buds of mice. DeChiara et al.
[23] showed that ROR2 is selectively expressed in chondro-
cytes of the growth plate of long-bones but not in those
bones formed by intra-membranous ossiﬁcation, indicating a
close relationship between growth plate cartilage and ROR2.
They showed that mice homozygous for the mutant allele
have disrupted growth of those bones that grow through
endochondral ossiﬁcation and they concluded that ROR2 is
essential both for initial patterning of the cartilage anlagen
and for subsequent regulation of mature cartilage [23]. These
observations have been replicated by other groups [32, 33,
35]. ROR2 mutations have been described in patients with
recessive Robinow syndrome [31, 36], which leads to limb
shortening, abnormal development of the spinal vertebrae
and brachydactyly (shortened digits), as well as craniofacial
abnormalities. Therefore, ROR2 is a biologically relevant cell
surface marker for cartilage formation as well as being of
practical use in tissue engineering.
We were further encouraged to investigate this molecule
because of its role as a receptor for Wnt5a [37–42]. This
receptor requires tyrosine kinase activity to mediate nonca-
nonical signaling [36, 38]. However, the downstream signaling
pathways are complex and only partially understood. Canoni-
cal Wnt signaling and activation of b-catenin inhibits chondro-
genesis, through binding of Sox-9 to b-catenin, so inhibiting
upregulation of type II collagen synthesis [43]. It has been
demonstrated that Wnt-5a signaling can antagonize the
canonical Wnt signaling pathway by promoting b-catenin deg-
radation [44]. This suggests that Wnt5a signaling through
ROR2 has the potential to upregulate chondrogenesis through
activation of SOX-9. On the other hand, Wnt1 and Wnt3a can
also bind to ROR2 and in this way activate the canonical path-
way [37, 45], which might be expected to inhibit chondrogen-
esis. ROR2 has also been shown to play a key role in bone
formation, as its expression is highly regulated during both
osteoblast differentiation [46, 47] and osteoclastogenesis [48].
Taken together, these studies indicate that ROR2 plays an
important role in musculoskeletal development, but the
mechanisms that are critical in vivo remain to be established.
Evidence that ROR2 expression is a feature of endogenous
cells is provided by our immunohistochemical data describing
ROR21 ve cells in the developing limb bud as well as in adult
bone marrow, combined with our ﬂow cytometry data dem-
onstrating expression of ROR2 by pericytes in adult human
bone marrow and adipose tissue. We have previously identi-
ﬁed the pericyte as a precursor of MSCs found in bone mar-
row and other organs [1, 2]. Our data, therefore, support a
possible role for ROR2 in the chondrogenic function of peri-
cytes as well as MSCs and suggest that this receptor has bio-
logical relevance.
The use of allogeneic MSCs as therapeutic tools in carti-
lage repair is limited by the variability of their chondrogenic
capacity from one donor to the next and the loss of chondro-
genic capacity with increasing passage (Supporting Informa-
tion Fig. S3). Selection of iROR21 ve cells ensures a higher
chondrogenic capacity and opens up the possibility of expand-
ing MSCs through multiple PDs while maintaining an
increased iROR2 expression and therefore enhanced chondro-
genesis. The expanded cells could then be used to treat carti-
lage damage either by direct implantation into the lesions or
indirectly, through injection into the synovial space.
CONCLUSION
To conclude, iROR2 is associated with pericytes in situ and
with MSCs ex vivo as well as with enhanced chondrogenesis
and thus can be exploited as a biological marker. It could
become central to the effective translation of MSC biology
into therapeutic strategies for cartilage repair in patients with
OA and other diseases of the joint and for extensive cartilage
loss in the nose and ear following trauma or cancer.
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